Emma Walmsley, GlaxoSmithKline CEO (Fang Zhe/Xinhua/Alamy Live News)

Glax­o­SmithK­line places a risky bet on Ar­row­head­'s RNA drug in the fail­ure-strewn NASH field

As ac­tivist in­vestors champ at the bit for change at drug gi­ant Glax­o­SmithK­line, the phar­ma gi­ant has turned over many rocks to find an R …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.